Verleden G M
University Hospital Gasthuisberg, Department of Respiratory Medicine, Lung Transplantation Unit, Leuven, Belgium.
Semin Respir Crit Care Med. 2001 Oct;22(5):551-8. doi: 10.1055/s-2001-18427.
Lung and heart-lung transplantation are currently recognized as effective treatment for selected patients with end-stage lung or heart-lung disease. Although the survival rates have improved in recent years, long-term survival is still hampered by the development of chronic rejection. Histologically chronic rejection is manifested by obliterative bronchiolitis (OB), a process that leads to airways obstruction, with a gradual decline in pulmonary function tests. Extensive research efforts have attempted to unravel the pathophysiology of OB and identify key cytokines and growth factors involved in the process. Since the histological diagnosis of chronic rejection remains difficult, a clinical grading system has been proposed, determined as bronchiolitis obliterans syndrome (BOS), divided into four and, more recently, five categories, depending on the severity of airflow obstruction. This paper reviews the current knowledge of chronic rejection after heart-lung and lung transplantation.
目前,肺移植和心肺移植被认为是治疗特定终末期肺病或心肺疾病患者的有效方法。尽管近年来生存率有所提高,但慢性排斥反应的发生仍然阻碍了长期生存。从组织学上看,慢性排斥反应表现为闭塞性细支气管炎(OB),这一过程会导致气道阻塞,肺功能测试结果逐渐下降。大量研究致力于阐明OB的病理生理学,并确定该过程中涉及的关键细胞因子和生长因子。由于慢性排斥反应的组织学诊断仍然困难,因此提出了一种临床分级系统,即闭塞性细支气管炎综合征(BOS),根据气流阻塞的严重程度分为四类,最近又分为五类。本文综述了心肺移植和肺移植后慢性排斥反应的现有知识。